Don M Gash Selected Research

Glial Cell Line-Derived Neurotrophic Factor (GDNF)

1/2020	GDNF and Parkinson's Disease: Where Next? A Summary from a Recent Workshop.
3/2010	Dopamine neuron stimulating actions of a GDNF propeptide.
12/2007	Six-month continuous intraputamenal infusion toxicity study of recombinant methionyl human glial cell line-derived neurotrophic factor (r-metHuGDNF in rhesus monkeys.
8/2007	Six-month continuous intraputamenal infusion toxicity study of recombinant methionyl human glial cell line-derived neurotrophic factor (r-metHuGDNF) in rhesus monkeys.
4/2007	Unilateral intraputamenal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year of treatment and 1 year of withdrawal.
12/2006	Point source concentration of GDNF may explain failure of phase II clinical trial.
5/2006	Unilateral intraputaminal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year each of treatment and withdrawal.
11/2005	Progenitor proliferation in the adult hippocampus and substantia nigra induced by glial cell line-derived neurotrophic factor.
8/2005	Trophic factor distribution predicts functional recovery in parkinsonian monkeys.
2/2005	Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Don M Gash Research Topics

Disease

20	Parkinson Disease (Parkinson's Disease) 01/2020 - 10/2002
5	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2020 - 10/2002
3	Parkinsonian Disorders (Parkinsonism) 02/2010 - 08/2005
1	Thrombosis (Thrombus) 01/2021
1	Necrosis 04/2017
1	Infections 04/2017
1	Huntington Disease (Huntington's Disease) 06/2015
1	MPTP Poisoning 02/2015
1	Neuroinflammatory Diseases 01/2009
1	Mitochondrial Diseases (Mitochondrial Disease) 01/2009
1	Weight Loss (Weight Reduction) 10/2007
1	Atrophy 02/2007
1	Movement Disorders (Movement Disorder) 01/2007
1	Hypokinesia (Bradykinesia) 11/2006

Drug/Important Bio-Agent (IBA)

13	Glial Cell Line-Derived Neurotrophic Factor (GDNF)IBA 01/2020 - 10/2002
4	Dopamine (Intropin)FDA LinkGeneric 02/2008 - 10/2002
3	1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)IBA 02/2015 - 11/2006
3	Nerve Growth Factors (Neurotrophins)IBA 03/2010 - 12/2004
2	Trichloroethylene (Trichloroethene)IBA 02/2010 - 02/2008
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2020
1	Pharmaceutical PreparationsIBA 04/2017
1	Tyrosine 3-Monooxygenase (Tyrosine Hydroxylase)IBA 04/2017
1	Small Interfering RNA (siRNA)IBA 06/2015
1	Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA 01/2009
1	MetalsIBA 02/2008
1	NeurotoxinsIBA 02/2008
1	Neurotransmitter Agents (Neurotransmitter)IBA 12/2007
1	Glutamic Acid (Glutamate)FDA Link 12/2007
1	IronIBA 02/2007
1	Dopamine Agents (Dopaminergic Agents)IBA 11/2006
1	Apomorphine FDA Link 11/2006
1	Amphetamine (Amfetamine)FDA LinkGeneric 11/2006
1	Peptides (Polypeptides)IBA 01/2003
1	Proteins (Proteins, Gene)FDA Link 01/2003
1	Levodopa (L Dopa)FDA LinkGeneric 10/2002

Therapy/Procedure

5	Therapeutics 01/2018 - 01/2003
2	Catheters 01/2021 - 04/2017
1	Caloric Restriction 12/2004